BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36872608)

  • 1. Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.
    Patel R; Aslam A; Parikh ND; Mervak B; Mubarak E; Higgins L; Lala K; Conner JF; Khaykin V; Bashir M; Do RKG; Burke LMB; Smith EN; Kim CY; Shampain KL; Owen D; Mendiratta-Lala M
    J Magn Reson Imaging; 2023 Jun; 57(6):1641-1654. PubMed ID: 36872608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 5. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
    Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
    Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy.
    Kampalath R; Tran-Harding K; Do RKG; Mendiratta-Lala M; Yaghmai V
    Magn Reson Imaging Clin N Am; 2021 Aug; 29(3):389-403. PubMed ID: 34243925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the CT/MRI LI-RADS Treatment Response Algorithm to Contrast-Enhanced Ultrasound: A Feasibility Study.
    Ruan SM; Cheng MQ; Huang H; Hu HT; Li W; Xie XY; Lu MD; Kuang M; Lin MX; Wang W
    J Hepatocell Carcinoma; 2022; 9():437-451. PubMed ID: 35620274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
    Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
    Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 13. Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy.
    Stocker D; King MJ; Homsi ME; Gnerre J; Marinelli B; Wurnig M; Schwartz M; Kim E; Taouli B
    Eur Radiol; 2024 Jan; 34(1):475-484. PubMed ID: 37540318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging diagnosis of hepatocellular carcinoma: LI-RADS.
    Cunha GM; Sirlin CB; Fowler KJ
    Chin Clin Oncol; 2021 Feb; 10(1):3. PubMed ID: 32527115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
    Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.